LB Pharmaceuticals names Joseph Miller as chief financial officer
The neuromedicines company said Miller starts as CFO effective September 2, 2026, ahead of pivotal NOVA-2 trial results for LB-102 in schizophrenia.
SEC filing
Latest
2 stories
Thursday, September 3
Thursday, August 6
Aurinia starts PRESERVE trial combining LUPKYNIS with biologics in lupus nephritis
The Phase 4 study will test LUPKYNIS alongside belimumab, obinutuzumab or anifrolumab in about 150 patients as Aurinia reports second-quarter results and reiterates 2026 revenue guidance.
SEC filing